Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bioflan is a phytotherapeutic (herbal) anti-inflammatory and analgesic medication developed and manufactured by the Brazilian pharmaceutical company Myralis. The product contains a standardized extract of *Harpagophytum procumbens* (Devil's Claw), with each tablet providing 250mg of the extract standardized to contain 30mg of harpagoside. Formulated as gastro-resistant coated tablets to protect the active ingredients from gastric acid, Bioflan is indicated for the symptomatic relief of moderate joint pain and acute lower back pain. It is commonly used to treat various rheumatic conditions, including arthritis, osteoarthritis, bursitis, and tendinitis. Bioflan is available as an over-the-counter (OTC) medication in Brazil and is distributed widely across the country.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Bioflan.